Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 18/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 18/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391498 | 0.86 | PDGFRB (0.57) | PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL6364034 | 0.84 | PDGFRB (0.55) | PDGFRBPDGFRA | |
| SCHEMBL3877724 | 0.83 | PDGFRB (0.55) | PDGFRBPDGFRA | |
| SCHEMBL620753 | 0.80 | PDGFRB (0.52) | PDGFRBPDGFRA | |
| SCHEMBL3214568 | 0.80 | PDGFRB (0.52) | PDGFRBPDGFRA | |
| SCHEMBL7081617 | 0.80 | PDGFRB (0.46) | PDGFRBPDGFRA | |
| SCHEMBL3873425 | 0.77 | HPGDS (0.58) | PDGFRBPDGFRA | |
| SCHEMBL28264937 | 0.76 | HPGDS (0.56) | PDGFRBPDGFRA | |
| SCHEMBL18318550 | 0.73 | PDGFRB (0.52) | PDGFRBPDGFRA | |
| SCHEMBL17942864 | 0.73 | PDPK1 (0.44) | PDGFRBPDGFRAPDPK1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| EP-1687276-B1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2009-10-14 | — | — | EP | disclosed |
| CN-100537540-C | Process for preparing 3-fluoroquinolines | AVENTIS PHARMA SA (FR) | 2009-09-09 | — | — | CN | disclosed |
| US-7396934-B2 | Process for preparing 3-fluoroquinolines | NOVEXEL (FR) | 2008-07-08 | — | — | US | disclosed |
| CN-1894216-A | Novel process for preparing 3-fluoroquinolines | AVENTIS PHARMA SA (FR) | 2007-01-10 | — | — | CN | disclosed |
| EP-1687276-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | AVENTIS PHARMA S.A. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005049575-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | PDGFRB 4750/4885PDGFRA 4741/4885PDPK1 4799/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | PDGFRB 4785/4885PDGFRA 4737/4885PDPK1 4493/4885 |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | QRFPR, NQO2, DHX35 | PDGFRB 3699/4885PDGFRA 2461/4885PDPK1 4224/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | PDGFRB 4785/4885PDGFRA 4737/4885PDPK1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.